Simvastatin treatment in inclusion body myositis (IBM) - ND

ISTITUTO NEUROLOGICO CARLO BESTA0 个研究点开始时间: 2007年11月21日最近更新: 2012年3月19日

试验速览

暂无简介。

•Patients affected by inclusion body myositis (diagnosis based on clinical, radiological and pathological data); males and females; aged between 18 and 80 years; patients able to give an informed consensus
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patients affected by a severe form of inclusion body myositis (disease duration > 10 years, severe dysphagia requiring an invasive nutritional support) or already treated with immunosuppressive drugs; patients in whom IVIG administration is not indicated (IgA deficiency, renal insufficiency, etc.); patients at high risk to develop rhabdomyolysis (patients with severe systemic diseases such as hepatopathies or thyroid dysfunction, patients in treatment with drugs that increase the risk of muscle toxicity, patients with CK basal levels five times higher than normal value); fertile women who intend to be pregnant or they are already pregnant.

发起方

ISTITUTO NEUROLOGICO CARLO BESTA